SK281754B6 - Derivát oxazolidinóndikarboxylovej kyseliny, spôsob jeho prípravy, farmaceutický prostriedok, ktorý ho obsahuje a jeho použitie - Google Patents
Derivát oxazolidinóndikarboxylovej kyseliny, spôsob jeho prípravy, farmaceutický prostriedok, ktorý ho obsahuje a jeho použitie Download PDFInfo
- Publication number
- SK281754B6 SK281754B6 SK1001-95A SK100195A SK281754B6 SK 281754 B6 SK281754 B6 SK 281754B6 SK 100195 A SK100195 A SK 100195A SK 281754 B6 SK281754 B6 SK 281754B6
- Authority
- SK
- Slovakia
- Prior art keywords
- oxo
- group
- acid
- formula
- tert
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 13
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims abstract description 8
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 6
- 239000012453 solvate Substances 0.000 claims abstract description 5
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims abstract description 3
- -1 oxazolidinone carboxylic acid derivative Chemical class 0.000 claims description 117
- 150000001875 compounds Chemical class 0.000 claims description 61
- 238000006243 chemical reaction Methods 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 13
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 13
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 125000000320 amidine group Chemical group 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 125000002560 nitrile group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000019260 propionic acid Nutrition 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- BXTWRMNZAGYXQQ-UHFFFAOYSA-N 1,2,4-oxadiazol-3-one Chemical group O=C1N=CON1 BXTWRMNZAGYXQQ-UHFFFAOYSA-N 0.000 claims description 3
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- PKQHKBCDHBTPAI-UHFFFAOYSA-N tert-butyl 1-[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC(C)(C)C)CCN1C(=O)C1OC(=O)N(C=2C=CC(=CC=2)C(N)=N)C1 PKQHKBCDHBTPAI-UHFFFAOYSA-N 0.000 claims description 3
- KRULFFCPPWGFGB-UHFFFAOYSA-N 3-[4-(n'-hydroxycarbamimidoyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound C1=CC(C(=NO)N)=CC=C1N1C(=O)OC(C(O)=O)C1 KRULFFCPPWGFGB-UHFFFAOYSA-N 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- JZJFHGJSPFTHOH-TZHYSIJRSA-N (2r)-2-[[3-(4-cyanophenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)C1OC(=O)N(C1)C=1C=CC(=CC=1)C#N)C1=CC=CC=C1 JZJFHGJSPFTHOH-TZHYSIJRSA-N 0.000 claims 1
- UILXLLSQORQLHI-UHFFFAOYSA-N 2-[1-[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperidin-4-yl]oxyacetic acid Chemical compound C1=CC(C(=N)N)=CC=C1N1C(=O)OC(C(=O)N2CCC(CC2)OCC(O)=O)C1 UILXLLSQORQLHI-UHFFFAOYSA-N 0.000 claims 1
- HKGLJYFJSQYHAA-UHFFFAOYSA-N 3-[[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]amino]propanoic acid Chemical compound C1=CC(C(=N)N)=CC=C1N1C(=O)OC(C(=O)NCCC(O)=O)C1 HKGLJYFJSQYHAA-UHFFFAOYSA-N 0.000 claims 1
- VEFFNECIDVRBTE-UHFFFAOYSA-N 2-oxo-3-phenyl-1,3-oxazolidine-5-carboxylic acid Chemical compound O=C1OC(C(=O)O)CN1C1=CC=CC=C1 VEFFNECIDVRBTE-UHFFFAOYSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- 229960000583 acetic acid Drugs 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- 239000002904 solvent Substances 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000012362 glacial acetic acid Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 238000010265 fast atom bombardment Methods 0.000 description 7
- 150000002825 nitriles Chemical class 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 238000010626 work up procedure Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000007327 hydrogenolysis reaction Methods 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 4
- ZHXOTNINARMZQO-UHFFFAOYSA-N 3-(4-cyanophenyl)-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound O=C1OC(C(=O)O)CN1C1=CC=C(C#N)C=C1 ZHXOTNINARMZQO-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- YHVYWBMUGQHEBA-UHFFFAOYSA-N NC1=CC(=C(C=C1)N1C(OC(C1)C(=O)O)=O)C=NO Chemical compound NC1=CC(=C(C=C1)N1C(OC(C1)C(=O)O)=O)C=NO YHVYWBMUGQHEBA-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- OIIFFMWVGFWKOT-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound C1=CC(CN)=CC=C1N1C(=O)OC(C(O)=O)C1 OIIFFMWVGFWKOT-UHFFFAOYSA-N 0.000 description 3
- UIWLSVUBPUPNBD-UHFFFAOYSA-N 3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1N1C(=O)OC(C(O)=O)C1 UIWLSVUBPUPNBD-UHFFFAOYSA-N 0.000 description 3
- QRDCHNNZLOAUGI-UHFFFAOYSA-N 3-[[2-oxo-3-[4-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-1,3-oxazolidine-5-carbonyl]amino]propanoic acid Chemical compound O=C1OC(C(=O)NCCC(=O)O)CN1C1=CC=C(C=2NC(=O)ON=2)C=C1 QRDCHNNZLOAUGI-UHFFFAOYSA-N 0.000 description 3
- 108010016626 Dipeptides Chemical group 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001409 amidines Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- PCOKVBQRZCEGTJ-UHFFFAOYSA-N tert-butyl 2-piperidin-4-yloxyacetate Chemical compound CC(C)(C)OC(=O)COC1CCNCC1 PCOKVBQRZCEGTJ-UHFFFAOYSA-N 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- FYFSQMJLYSHULJ-UHFFFAOYSA-N 3-[4-[[(4-cyanophenyl)carbamoylamino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound O=C1OC(C(=O)O)CN1C(C=C1)=CC=C1CNC(=O)NC1=CC=C(C#N)C=C1 FYFSQMJLYSHULJ-UHFFFAOYSA-N 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010012088 Fibrinogen Receptors Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- IJFAJEJRHKCVND-UHFFFAOYSA-N benzyl 1-[3-(4-cyanophenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperidine-4-carboxylate Chemical compound C1CN(C(=O)C2OC(=O)N(C2)C=2C=CC(=CC=2)C#N)CCC1C(=O)OCC1=CC=CC=C1 IJFAJEJRHKCVND-UHFFFAOYSA-N 0.000 description 2
- SCISJWIMJKMERB-UHFFFAOYSA-N benzyl 2-[4-[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]acetate Chemical compound C1=CC(C(=N)N)=CC=C1N1C(=O)OC(C(=O)N2CCN(CC(=O)OCC=3C=CC=CC=3)CC2)C1 SCISJWIMJKMERB-UHFFFAOYSA-N 0.000 description 2
- IHPBCDRXONTRLB-UHFFFAOYSA-N benzyl 2-[4-[3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]acetate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1N1C(=O)OC(C(=O)N2CCN(CC(=O)OCC=3C=CC=CC=3)CC2)C1 IHPBCDRXONTRLB-UHFFFAOYSA-N 0.000 description 2
- BLBHAAHASZMYPI-UHFFFAOYSA-N benzyl piperidine-4-carboxylate Chemical compound C1CNCCC1C(=O)OCC1=CC=CC=C1 BLBHAAHASZMYPI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003245 coal Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N hydroxylamine hydrochloride Substances Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- WCYJQVALWQMJGE-UHFFFAOYSA-M hydroxylammonium chloride Chemical compound [Cl-].O[NH3+] WCYJQVALWQMJGE-UHFFFAOYSA-M 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- CIUBYJSMYHKERV-RZZZFEHKSA-N methyl (2r)-2-[[2-oxo-3-[4-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-1,3-oxazolidine-5-carbonyl]amino]propanoate Chemical compound O=C1OC(C(=O)N[C@H](C)C(=O)OC)CN1C1=CC=C(C=2NOC(=O)N=2)C=C1 CIUBYJSMYHKERV-RZZZFEHKSA-N 0.000 description 2
- PLAXLQDMKXYQDL-UHFFFAOYSA-N methyl 3-[[2-oxo-3-[4-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-1,3-oxazolidine-5-carbonyl]amino]propanoate Chemical compound O=C1OC(C(=O)NCCC(=O)OC)CN1C1=CC=C(C=2NC(=O)ON=2)C=C1 PLAXLQDMKXYQDL-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- MTMGGIZFQRKZQQ-MRTLOADZSA-N tert-butyl (2r)-2-[[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]amino]-3-(4-hydroxyphenyl)propanoate Chemical compound C([C@H](C(=O)OC(C)(C)C)NC(=O)C1OC(=O)N(C1)C=1C=CC(=CC=1)C(N)=N)C1=CC=C(O)C=C1 MTMGGIZFQRKZQQ-MRTLOADZSA-N 0.000 description 2
- QOKLIMFXJLHYLP-FIWHBWSRSA-N tert-butyl (2r)-2-[[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]amino]-3-(4-methoxyphenyl)propanoate Chemical compound C1=CC(OC)=CC=C1C[C@H](C(=O)OC(C)(C)C)NC(=O)C1OC(=O)N(C=2C=CC(=CC=2)C(N)=N)C1 QOKLIMFXJLHYLP-FIWHBWSRSA-N 0.000 description 2
- JNALUHVKBJSLGQ-VUUHIHSGSA-N tert-butyl (2r)-2-[[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]amino]propanoate Chemical compound O=C1OC(C(=O)N[C@H](C)C(=O)OC(C)(C)C)CN1C1=CC=C(C(N)=N)C=C1 JNALUHVKBJSLGQ-VUUHIHSGSA-N 0.000 description 2
- PUYKSEUKNGMADE-MRTLOADZSA-N tert-butyl (2r)-2-[[3-(4-carbamothioylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]amino]-3-phenylpropanoate Chemical compound C([C@H](C(=O)OC(C)(C)C)NC(=O)C1OC(=O)N(C1)C=1C=CC(=CC=1)C(N)=S)C1=CC=CC=C1 PUYKSEUKNGMADE-MRTLOADZSA-N 0.000 description 2
- WADNNCOUZGCOHW-UHFFFAOYSA-N tert-butyl 1-[3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carbonyl]piperidine-4-carboxylate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1N1C(=O)OC(C(=O)N2CCC(CC2)C(=O)OC(C)(C)C)C1 WADNNCOUZGCOHW-UHFFFAOYSA-N 0.000 description 2
- QGDNTGUKRDHTPY-UHFFFAOYSA-N tert-butyl 2-[1-[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperidin-3-yl]oxyacetate Chemical compound C1C(OCC(=O)OC(C)(C)C)CCCN1C(=O)C1OC(=O)N(C=2C=CC(=CC=2)C(N)=N)C1 QGDNTGUKRDHTPY-UHFFFAOYSA-N 0.000 description 2
- XJMYQAWCSVMZJJ-UHFFFAOYSA-N tert-butyl 2-[1-[3-(4-cyanophenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperidin-4-yl]oxyacetate Chemical compound C1CC(OCC(=O)OC(C)(C)C)CCN1C(=O)C1OC(=O)N(C=2C=CC(=CC=2)C#N)C1 XJMYQAWCSVMZJJ-UHFFFAOYSA-N 0.000 description 2
- AOPWEKJHRJJHOH-UHFFFAOYSA-N tert-butyl 2-[1-[3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carbonyl]piperidin-4-yl]oxyacetate Chemical compound C1CC(OCC(=O)OC(C)(C)C)CCN1C(=O)C1OC(=O)N(C=2C=CC(CNC(=O)OC(C)(C)C)=CC=2)C1 AOPWEKJHRJJHOH-UHFFFAOYSA-N 0.000 description 2
- HUTNZWYMMOBSHP-UHFFFAOYSA-N tert-butyl 2-[4-[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]-2-oxopiperazin-1-yl]acetate Chemical compound C1C(=O)N(CC(=O)OC(C)(C)C)CCN1C(=O)C1OC(=O)N(C=2C=CC(=CC=2)C(N)=N)C1 HUTNZWYMMOBSHP-UHFFFAOYSA-N 0.000 description 2
- UBQQORBWURMBLS-UHFFFAOYSA-N tert-butyl 3-[[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]amino]propanoate Chemical compound O=C1OC(C(=O)NCCC(=O)OC(C)(C)C)CN1C1=CC=C(C(N)=N)C=C1 UBQQORBWURMBLS-UHFFFAOYSA-N 0.000 description 2
- FUYBPBOHNIHCHM-UHFFFAOYSA-N tert-butyl piperidine-4-carboxylate Chemical compound CC(C)(C)OC(=O)C1CCNCC1 FUYBPBOHNIHCHM-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- VNUPFDWUNAGMPO-YHMJZVADSA-N (2r)-2-[[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]amino]butanedioic acid Chemical compound C1=CC(C(=N)N)=CC=C1N1C(=O)OC(C(=O)N[C@H](CC(O)=O)C(O)=O)C1 VNUPFDWUNAGMPO-YHMJZVADSA-N 0.000 description 1
- LRKIOMZCCRAUHJ-TZHYSIJRSA-N (2r)-3-[3-[4-(aminomethyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]-2-benzyl-3-oxopropanoic acid Chemical compound C1=CC(CN)=CC=C1N1C(=O)OC(C(=O)[C@@H](CC=2C=CC=CC=2)C(O)=O)C1 LRKIOMZCCRAUHJ-TZHYSIJRSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- KNWCDYSKJSREAQ-UHFFFAOYSA-N 1,3-oxazolidine-2-carboxylic acid Chemical compound OC(=O)C1NCCO1 KNWCDYSKJSREAQ-UHFFFAOYSA-N 0.000 description 1
- PLRPKVNZGONHKD-UHFFFAOYSA-N 1,3-oxazolidine-5-carboxylic acid Chemical compound OC(=O)C1CNCO1 PLRPKVNZGONHKD-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- HLMLSXZOGWKRNB-UHFFFAOYSA-N 1-[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperidine-4-carboxylic acid hydrochloride Chemical compound Cl.NC(=N)c1ccc(cc1)N1CC(OC1=O)C(=O)N1CCC(CC1)C(O)=O HLMLSXZOGWKRNB-UHFFFAOYSA-N 0.000 description 1
- JJXFLMIJACQQMS-UHFFFAOYSA-N 1-butylpiperidine-4-carboxylic acid Chemical compound CCCCN1CCC(C(O)=O)CC1 JJXFLMIJACQQMS-UHFFFAOYSA-N 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- UHNMIDKSDRGICN-UHFFFAOYSA-N 2-(2-phenylethylazaniumyl)acetate Chemical compound OC(=O)CNCCC1=CC=CC=C1 UHNMIDKSDRGICN-UHFFFAOYSA-N 0.000 description 1
- FRYOUKNFWFXASU-UHFFFAOYSA-N 2-(methylamino)acetic acid Chemical compound CNCC(O)=O.CNCC(O)=O FRYOUKNFWFXASU-UHFFFAOYSA-N 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- GMDJMLOOHULQEV-UHFFFAOYSA-N 2-(n-ethylanilino)acetic acid Chemical compound OC(=O)CN(CC)C1=CC=CC=C1 GMDJMLOOHULQEV-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- JZJOGFHMTCFZNY-UHFFFAOYSA-N 2-[1-[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperidin-3-yl]oxyacetic acid Chemical compound C1=CC(C(=N)N)=CC=C1N1C(=O)OC(C(=O)N2CC(CCC2)OCC(O)=O)C1 JZJOGFHMTCFZNY-UHFFFAOYSA-N 0.000 description 1
- HOMWOSCOPZZUJA-UHFFFAOYSA-N 2-[4-[3-[4-(aminomethyl)phenyl]-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]acetic acid dihydrochloride Chemical compound Cl.Cl.NCc1ccc(cc1)N1CC(OC1=O)C(=O)N1CCN(CC(O)=O)CC1 HOMWOSCOPZZUJA-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- ITQZGBLSWNNLFL-UHFFFAOYSA-N 2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound OC(=O)C1CNC(=O)O1 ITQZGBLSWNNLFL-UHFFFAOYSA-N 0.000 description 1
- WRJZKSHNBALIGH-UHFFFAOYSA-N 2-piperazin-1-ium-1-ylacetate Chemical compound OC(=O)CN1CCNCC1 WRJZKSHNBALIGH-UHFFFAOYSA-N 0.000 description 1
- OUKGNAJYMLCSLE-UHFFFAOYSA-N 2-piperidin-4-ylbutanoic acid Chemical compound CCC(C(O)=O)C1CCNCC1 OUKGNAJYMLCSLE-UHFFFAOYSA-N 0.000 description 1
- PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical group O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 description 1
- GAZRNXIMWKZADY-UHFFFAOYSA-N 3,5-dimethylpyrazole-1-carboximidamide Chemical group CC=1C=C(C)N(C(N)=N)N=1 GAZRNXIMWKZADY-UHFFFAOYSA-N 0.000 description 1
- DYJFVIXCJFSAFC-UHFFFAOYSA-N 3-(2-phenylethylazaniumyl)propanoate Chemical compound OC(=O)CCNCCC1=CC=CC=C1 DYJFVIXCJFSAFC-UHFFFAOYSA-N 0.000 description 1
- LKHPFYUESUUDLR-UHFFFAOYSA-N 3-(4-cyanophenyl)-2-oxo-1,3-oxazolidine-5-carbonyl chloride Chemical compound O=C1OC(C(=O)Cl)CN1C1=CC=C(C#N)C=C1 LKHPFYUESUUDLR-UHFFFAOYSA-N 0.000 description 1
- NOBJTRIJAPGBCB-UHFFFAOYSA-N 3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)N2C(OC(C2)C(O)=O)=O)=N1 NOBJTRIJAPGBCB-UHFFFAOYSA-N 0.000 description 1
- DBVJLABROUXZMH-UHFFFAOYSA-N 3-[4-(N'-hydroxycarbamimidoyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid hydrochloride Chemical compound Cl.NC(=NO)c1ccc(cc1)N1CC(OC1=O)C(O)=O DBVJLABROUXZMH-UHFFFAOYSA-N 0.000 description 1
- SMLQCCJFDFRCGC-UHFFFAOYSA-N 3-[4-[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]propanoic acid Chemical compound C1=CC(C(=N)N)=CC=C1N1C(=O)OC(C(=O)N2CCN(CCC(O)=O)CC2)C1 SMLQCCJFDFRCGC-UHFFFAOYSA-N 0.000 description 1
- FZFJWMYPOSKNTM-UHFFFAOYSA-N 3-[4-[3-[4-(aminomethyl)phenyl]-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]propanoic acid dihydrochloride Chemical compound Cl.Cl.NCc1ccc(cc1)N1CC(OC1=O)C(=O)N1CCN(CCC(O)=O)CC1 FZFJWMYPOSKNTM-UHFFFAOYSA-N 0.000 description 1
- REIYQDACGZHMII-UHFFFAOYSA-N 3-[4-[3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]propanoic acid Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1N1C(=O)OC(C(=O)N2CCN(CCC(O)=O)CC2)C1 REIYQDACGZHMII-UHFFFAOYSA-N 0.000 description 1
- XFJVBCCGKRTFHF-UHFFFAOYSA-N 3-[4-[5-(chloromethyl)-1,2,4-oxadiazol-3-yl]phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound O=C1OC(C(=O)O)CN1C1=CC=C(C=2N=C(CCl)ON=2)C=C1 XFJVBCCGKRTFHF-UHFFFAOYSA-N 0.000 description 1
- GHSYCZYCKOUDKO-UHFFFAOYSA-N 3-[4-[5-[(1,3-dioxoisoindol-2-yl)methyl]-1,2,4-oxadiazol-3-yl]phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound O=C1OC(C(=O)O)CN1C1=CC=C(C=2N=C(CN3C(C4=CC=CC=C4C3=O)=O)ON=2)C=C1 GHSYCZYCKOUDKO-UHFFFAOYSA-N 0.000 description 1
- SHWZOVUVCHDJRV-UHFFFAOYSA-N 3-[4-[[(4-carbamimidoylphenyl)carbamoylamino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound C1=CC(C(=N)N)=CC=C1NC(=O)NCC1=CC=C(N2C(OC(C2)C(O)=O)=O)C=C1 SHWZOVUVCHDJRV-UHFFFAOYSA-N 0.000 description 1
- WMJOYVFVUMJKKZ-UHFFFAOYSA-N 3-[4-[[(4-carbamothioylbenzoyl)amino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound C1=CC(C(=S)N)=CC=C1C(=O)NCC1=CC=C(N2C(OC(C2)C(O)=O)=O)C=C1 WMJOYVFVUMJKKZ-UHFFFAOYSA-N 0.000 description 1
- SWCPLKVQQJVJSN-UHFFFAOYSA-N 3-[4-[[(4-cyanobenzoyl)amino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound O=C1OC(C(=O)O)CN1C(C=C1)=CC=C1CNC(=O)C1=CC=C(C#N)C=C1 SWCPLKVQQJVJSN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 1
- USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OOUCFDZEFCSLOX-UHFFFAOYSA-N C(C)C(C(=O)O)C1CCN(CC1)C(=O)C1CN(C(O1)=O)C1=CC=C(C=C1)C(N)=N Chemical compound C(C)C(C(=O)O)C1CCN(CC1)C(=O)C1CN(C(O1)=O)C1=CC=C(C=C1)C(N)=N OOUCFDZEFCSLOX-UHFFFAOYSA-N 0.000 description 1
- PHFVZSHBFRVWAT-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)C1CCN(CC1)C(=O)C1CN(C(O1)=O)C1=C(CC(C=C1)=N)CSC Chemical compound C(C1=CC=CC=C1)OC(=O)C1CCN(CC1)C(=O)C1CN(C(O1)=O)C1=C(CC(C=C1)=N)CSC PHFVZSHBFRVWAT-UHFFFAOYSA-N 0.000 description 1
- VXWICYCCFMWCJQ-UHFFFAOYSA-N C1=CC=C(C(=C1)C(=O)N)C(=O)NCC(=O)Cl Chemical compound C1=CC=C(C(=C1)C(=O)N)C(=O)NCC(=O)Cl VXWICYCCFMWCJQ-UHFFFAOYSA-N 0.000 description 1
- MUIWEVZPOQDDQQ-UHFFFAOYSA-N C1CN(CCN1C(=O)C2CN(C(=O)O2)C3=CC=C(C=C3)C#N)OCC(=O)OCC4=CC=CC=C4 Chemical compound C1CN(CCN1C(=O)C2CN(C(=O)O2)C3=CC=C(C=C3)C#N)OCC(=O)OCC4=CC=CC=C4 MUIWEVZPOQDDQQ-UHFFFAOYSA-N 0.000 description 1
- MOESBOVWPLWVQV-UHFFFAOYSA-N C=1C=C(N2C(OC(C2)C(O)=O)=O)C=CC=1C(CSC)NC(=O)C1=CCC(=N)C=C1 Chemical compound C=1C=C(N2C(OC(C2)C(O)=O)=O)C=CC=1C(CSC)NC(=O)C1=CCC(=N)C=C1 MOESBOVWPLWVQV-UHFFFAOYSA-N 0.000 description 1
- OCNXTYVTNWERCD-UHFFFAOYSA-N C=1C=CC=CC=1COC(=O)C(C)N1CCNCC1 Chemical compound C=1C=CC=CC=1COC(=O)C(C)N1CCNCC1 OCNXTYVTNWERCD-UHFFFAOYSA-N 0.000 description 1
- NACVOFQORPWUCB-UHFFFAOYSA-N CC(C)(C)OC(=O)CCCC1CCN(CC1)C(=O)C2CN(C(=O)O2)C3=CC=C(C=C3)C(=N)N Chemical compound CC(C)(C)OC(=O)CCCC1CCN(CC1)C(=O)C2CN(C(=O)O2)C3=CC=C(C=C3)C(=N)N NACVOFQORPWUCB-UHFFFAOYSA-N 0.000 description 1
- BFIJJAGALIIUFC-UHFFFAOYSA-N CC(C)(C)OC(=O)NCC1=CC=C(C=C1)N2CC(OC2=O)C(=O)OCC3=CC=CC=C3 Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C=C1)N2CC(OC2=O)C(=O)OCC3=CC=CC=C3 BFIJJAGALIIUFC-UHFFFAOYSA-N 0.000 description 1
- DFIRDSVXZOTJOJ-WNWQKLGWSA-N CC(C)(C)[C@](CC1=CC=CC=C1)(C(OC(C)(C)C)=O)NC(C(CN1C(C=C2)=CC=C2C#N)OC1=O)=O Chemical compound CC(C)(C)[C@](CC1=CC=CC=C1)(C(OC(C)(C)C)=O)NC(C(CN1C(C=C2)=CC=C2C#N)OC1=O)=O DFIRDSVXZOTJOJ-WNWQKLGWSA-N 0.000 description 1
- AJIBUHXZTHIZKH-QVWGJOIVSA-N CC(C)(C)[C@](CC1=CC=CC=C1)(C(OC(C)(C)C)=O)NC(C(CN1C(C=C2)=CC=C2C(N)=N)OC1=O)=O Chemical compound CC(C)(C)[C@](CC1=CC=CC=C1)(C(OC(C)(C)C)=O)NC(C(CN1C(C=C2)=CC=C2C(N)=N)OC1=O)=O AJIBUHXZTHIZKH-QVWGJOIVSA-N 0.000 description 1
- APPPYUDUOHHVRT-UHFFFAOYSA-N CCC(CN1CCN(CC1)C(=O)C2CN(C(=O)O2)C3=CC=C(C=C3)C(=N)N)C(=O)OCC4=CC=CC=C4 Chemical compound CCC(CN1CCN(CC1)C(=O)C2CN(C(=O)O2)C3=CC=C(C=C3)C(=N)N)C(=O)OCC4=CC=CC=C4 APPPYUDUOHHVRT-UHFFFAOYSA-N 0.000 description 1
- PRHSBLINJUCMHM-UHFFFAOYSA-N CSCC1=C(C=CC(=N)C1)NC(=O)NCC2=CC=C(C=C2)N3CC(OC3=O)C(=O)OCC4=CC=CC=C4 Chemical compound CSCC1=C(C=CC(=N)C1)NC(=O)NCC2=CC=C(C=C2)N3CC(OC3=O)C(=O)OCC4=CC=CC=C4 PRHSBLINJUCMHM-UHFFFAOYSA-N 0.000 description 1
- VFCFTDDRNZHQDK-FKSKYRLFSA-N C[C@H](C1=CC=CC=C1NC(=O)C2CN(C(=O)O2)C3=CC=C(C=C3)CNC(=O)OC(C)(C)C)C(=O)OC(C)(C)C Chemical compound C[C@H](C1=CC=CC=C1NC(=O)C2CN(C(=O)O2)C3=CC=C(C=C3)CNC(=O)OC(C)(C)C)C(=O)OC(C)(C)C VFCFTDDRNZHQDK-FKSKYRLFSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- DBXFXFQKXINSKG-UHFFFAOYSA-N Cl.C(N)(=N)C1=CC=C(C=C1)N1C(OC(C1)C(=O)O)=O Chemical compound Cl.C(N)(=N)C1=CC=C(C=C1)N1C(OC(C1)C(=O)O)=O DBXFXFQKXINSKG-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 1
- 101000911790 Homo sapiens Sister chromatid cohesion protein DCC1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- PLPVVHLPRPYBFB-UHFFFAOYSA-N N=C1CC(=C(C=C1)N1C(OC(C1)C(=O)N1CCN(CC1)CC(=O)OCC1=CC=CC=C1)=O)CSC Chemical compound N=C1CC(=C(C=C1)N1C(OC(C1)C(=O)N1CCN(CC1)CC(=O)OCC1=CC=CC=C1)=O)CSC PLPVVHLPRPYBFB-UHFFFAOYSA-N 0.000 description 1
- HQVXSYOSPSWGNE-YMBRHYMPSA-N N=C1CC(=C(C=C1)N1C(OC(C1)C(=O)N[C@@H](C(=O)OC(C)(C)C)CC1=CC=CC=C1)=O)CSC Chemical compound N=C1CC(=C(C=C1)N1C(OC(C1)C(=O)N[C@@H](C(=O)OC(C)(C)C)CC1=CC=CC=C1)=O)CSC HQVXSYOSPSWGNE-YMBRHYMPSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- GEYBMYRBIABFTA-UHFFFAOYSA-N O-methyltyrosine Chemical compound COC1=CC=C(CC(N)C(O)=O)C=C1 GEYBMYRBIABFTA-UHFFFAOYSA-N 0.000 description 1
- VCAHEZZLLXZYTL-UHFFFAOYSA-N ON=CC1=CC(N)=CC=C1N1C(=O)OC(C(=O)N2CCC(CC2)C(=O)OCC=2C=CC=CC=2)C1 Chemical compound ON=CC1=CC(N)=CC=C1N1C(=O)OC(C(=O)N2CCC(CC2)C(=O)OCC=2C=CC=CC=2)C1 VCAHEZZLLXZYTL-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229910019891 RuCl3 Inorganic materials 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100027040 Sister chromatid cohesion protein DCC1 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
- YVPAVFZMCRKIMS-UHFFFAOYSA-N acetic acid benzyl acetate Chemical compound CC(O)=O.CC(=O)OCC1=CC=CC=C1 YVPAVFZMCRKIMS-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- PXRIAVXPRVICRE-UHFFFAOYSA-N benzenesulfonic acid;4-methylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.CC1=CC=C(S(O)(=O)=O)C=C1 PXRIAVXPRVICRE-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- FHINEEHQTYAZCV-UHFFFAOYSA-N benzyl 1-[3-(4-carbamothioylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperidine-4-carboxylate Chemical compound C1=CC(C(=S)N)=CC=C1N1C(=O)OC(C(=O)N2CCC(CC2)C(=O)OCC=2C=CC=CC=2)C1 FHINEEHQTYAZCV-UHFFFAOYSA-N 0.000 description 1
- QEVPCOUYJFGHAJ-UHFFFAOYSA-N benzyl 1-[3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carbonyl]piperidine-4-carboxylate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1N1C(=O)OC(C(=O)N2CCC(CC2)C(=O)OCC=2C=CC=CC=2)C1 QEVPCOUYJFGHAJ-UHFFFAOYSA-N 0.000 description 1
- KDQHZFZXRSUECG-UHFFFAOYSA-N benzyl 2-[4-[2-oxo-3-[4-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]acetate Chemical compound C=1C=CC=CC=1COC(=O)CN(CC1)CCN1C(=O)C(OC1=O)CN1C(C=C1)=CC=C1C1=NOC(=O)N1 KDQHZFZXRSUECG-UHFFFAOYSA-N 0.000 description 1
- JXXZYIGRIZXPDS-UHFFFAOYSA-N benzyl 2-[4-[3-(4-carbamothioylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]acetate Chemical compound C1=CC(C(=S)N)=CC=C1N1C(=O)OC(C(=O)N2CCN(CC(=O)OCC=3C=CC=CC=3)CC2)C1 JXXZYIGRIZXPDS-UHFFFAOYSA-N 0.000 description 1
- AJDZVQFYEDMDDA-UHFFFAOYSA-N benzyl 2-[4-[3-(4-cyanophenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]acetate Chemical compound C=1C=CC=CC=1COC(=O)CN(CC1)CCN1C(=O)C(OC1=O)CN1C1=CC=C(C#N)C=C1 AJDZVQFYEDMDDA-UHFFFAOYSA-N 0.000 description 1
- NRSCLWQRTZBHBL-UHFFFAOYSA-N benzyl 2-[4-[3-[4-(aminomethyl)phenyl]-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]acetate dihydrochloride Chemical compound Cl.Cl.NCc1ccc(cc1)N1CC(OC1=O)C(=O)N1CCN(CC(=O)OCc2ccccc2)CC1 NRSCLWQRTZBHBL-UHFFFAOYSA-N 0.000 description 1
- FDTQLXHLYYPMEG-UHFFFAOYSA-N benzyl 2-piperazin-1-ylacetate Chemical compound C=1C=CC=CC=1COC(=O)CN1CCNCC1 FDTQLXHLYYPMEG-UHFFFAOYSA-N 0.000 description 1
- SDZLDZUFPTXVNX-UHFFFAOYSA-N benzyl 3-[4-[2-oxo-3-[4-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]propanoate Chemical compound C=1C=CC=CC=1COC(=O)CCN(CC1)CCN1C(=O)C(OC1=O)CN1C(C=C1)=CC=C1C1=NOC(=O)N1 SDZLDZUFPTXVNX-UHFFFAOYSA-N 0.000 description 1
- UPLMXMKPICQFLY-UHFFFAOYSA-N benzyl 3-[4-[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]propanoate Chemical compound C1=CC(C(=N)N)=CC=C1N1C(=O)OC(C(=O)N2CCN(CCC(=O)OCC=3C=CC=CC=3)CC2)C1 UPLMXMKPICQFLY-UHFFFAOYSA-N 0.000 description 1
- SCWMLENHMYWIPL-UHFFFAOYSA-N benzyl 3-[4-[3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]-2-oxo-1,3-oxazolidine-5-carbonyl]piperazin-1-yl]propanoate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1N1C(=O)OC(C(=O)N2CCN(CCC(=O)OCC=3C=CC=CC=3)CC2)C1 SCWMLENHMYWIPL-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- BTMVHUNTONAYDX-UHFFFAOYSA-N butyl propionate Chemical compound CCCCOC(=O)CC BTMVHUNTONAYDX-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- FNCGNFXGKHSMKJ-MRVPVSSYSA-N ditert-butyl (2r)-2-aminobutanedioate Chemical compound CC(C)(C)OC(=O)C[C@@H](N)C(=O)OC(C)(C)C FNCGNFXGKHSMKJ-MRVPVSSYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- BIVBERUVDUFKND-UHFFFAOYSA-N ethyl 2-[1-[2-oxo-3-[4-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-1,3-oxazolidine-5-carbonyl]piperidin-4-yl]acetate Chemical compound C1CC(CC(=O)OCC)CCN1C(=O)C1OC(=O)N(C=2C=CC(=CC=2)C=2NC(=O)ON=2)C1 BIVBERUVDUFKND-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- DWKPPFQULDPWHX-GSVOUGTGSA-N methyl (2r)-2-aminopropanoate Chemical compound COC(=O)[C@@H](C)N DWKPPFQULDPWHX-GSVOUGTGSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- AAFNCROTPCODFP-UHFFFAOYSA-N n-(4-cyanophenyl)carbamoyl chloride Chemical compound ClC(=O)NC1=CC=C(C#N)C=C1 AAFNCROTPCODFP-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- JBOTWOLOQJHMHU-OQHSHRKDSA-N tert-butyl (2r)-2-[[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]-(2-phenylethyl)amino]propanoate Chemical compound C1N(C=2C=CC(=CC=2)C(N)=N)C(=O)OC1C(=O)N([C@H](C)C(=O)OC(C)(C)C)CCC1=CC=CC=C1 JBOTWOLOQJHMHU-OQHSHRKDSA-N 0.000 description 1
- ICJQOSRKQLCBLT-MRTLOADZSA-N tert-butyl (2r)-2-[[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]amino]-3-phenylpropanoate Chemical compound C([C@H](C(=O)OC(C)(C)C)NC(=O)C1OC(=O)N(C1)C=1C=CC(=CC=1)C(N)=N)C1=CC=CC=C1 ICJQOSRKQLCBLT-MRTLOADZSA-N 0.000 description 1
- QOISWWBTZMFUEL-LLVKDONJSA-N tert-butyl (2r)-2-amino-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)[C@H](N)CC1=CC=CC=C1 QOISWWBTZMFUEL-LLVKDONJSA-N 0.000 description 1
- TZHVYFBSLOMRCU-RXMQYKEDSA-N tert-butyl (2r)-2-aminopropanoate Chemical compound C[C@@H](N)C(=O)OC(C)(C)C TZHVYFBSLOMRCU-RXMQYKEDSA-N 0.000 description 1
- KLJLNABDSDXQBP-WTQRLHSKSA-N tert-butyl (2r)-2-benzyl-3-[3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]-3-oxopropanoate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1N1C(=O)OC(C(=O)[C@@H](CC=2C=CC=CC=2)C(=O)OC(C)(C)C)C1 KLJLNABDSDXQBP-WTQRLHSKSA-N 0.000 description 1
- QOISWWBTZMFUEL-NSHDSACASA-N tert-butyl (2s)-2-amino-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)[C@@H](N)CC1=CC=CC=C1 QOISWWBTZMFUEL-NSHDSACASA-N 0.000 description 1
- GCQGGODJFXCQIE-UHFFFAOYSA-N tert-butyl 2-(2-oxopiperazin-1-yl)acetate Chemical compound CC(C)(C)OC(=O)CN1CCNCC1=O GCQGGODJFXCQIE-UHFFFAOYSA-N 0.000 description 1
- LUKDOCDDQKRGKG-UHFFFAOYSA-N tert-butyl 2-[1-[2-oxo-3-[4-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-1,3-oxazolidine-5-carbonyl]piperidin-4-yl]acetate Chemical compound C1CC(CC(=O)OC(C)(C)C)CCN1C(=O)C1OC(=O)N(C=2C=CC(=CC=2)C=2NC(=O)ON=2)C1 LUKDOCDDQKRGKG-UHFFFAOYSA-N 0.000 description 1
- NQVCPBQRHCEPEF-UHFFFAOYSA-N tert-butyl 2-[1-[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]piperidin-4-yl]oxyacetate Chemical compound C1CC(OCC(=O)OC(C)(C)C)CCN1C(=O)C1OC(=O)N(C=2C=CC(=CC=2)C(N)=N)C1 NQVCPBQRHCEPEF-UHFFFAOYSA-N 0.000 description 1
- HIAIZEPNWNXJBP-UHFFFAOYSA-N tert-butyl 2-piperidin-4-ylacetate Chemical compound CC(C)(C)OC(=O)CC1CCNCC1 HIAIZEPNWNXJBP-UHFFFAOYSA-N 0.000 description 1
- CGBKZFQYNUUAME-UHFFFAOYSA-N tert-butyl 3-[[2-oxo-3-[4-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-1,3-oxazolidine-5-carbonyl]-(2-phenylethyl)amino]propanoate Chemical compound C1N(C=2C=CC(=CC=2)C=2NC(=O)ON=2)C(=O)OC1C(=O)N(CCC(=O)OC(C)(C)C)CCC1=CC=CC=C1 CGBKZFQYNUUAME-UHFFFAOYSA-N 0.000 description 1
- RKKCPXZUAFZRSM-UHFFFAOYSA-N tert-butyl 3-[[3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidine-5-carbonyl]-(2-phenylethyl)amino]propanoate Chemical compound C1N(C=2C=CC(=CC=2)C(N)=N)C(=O)OC1C(=O)N(CCC(=O)OC(C)(C)C)CCC1=CC=CC=C1 RKKCPXZUAFZRSM-UHFFFAOYSA-N 0.000 description 1
- ZJXHVYSDMUKUCA-UHFFFAOYSA-N tert-butyl 3-aminopropanoate Chemical compound CC(C)(C)OC(=O)CCN ZJXHVYSDMUKUCA-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4429461A DE4429461A1 (de) | 1994-08-19 | 1994-08-19 | Adhäsionsrezeptor-Antagonisten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK100195A3 SK100195A3 (en) | 1996-06-05 |
| SK281754B6 true SK281754B6 (sk) | 2001-07-10 |
Family
ID=6526098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1001-95A SK281754B6 (sk) | 1994-08-19 | 1995-08-11 | Derivát oxazolidinóndikarboxylovej kyseliny, spôsob jeho prípravy, farmaceutický prostriedok, ktorý ho obsahuje a jeho použitie |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5614535A (cs) |
| EP (1) | EP0697408B1 (cs) |
| JP (1) | JP3810833B2 (cs) |
| KR (1) | KR100365870B1 (cs) |
| CN (1) | CN1204889C (cs) |
| AT (1) | ATE212339T1 (cs) |
| AU (1) | AU698412B2 (cs) |
| CA (1) | CA2156360C (cs) |
| CZ (1) | CZ290984B6 (cs) |
| DE (2) | DE4429461A1 (cs) |
| DK (1) | DK0697408T3 (cs) |
| ES (1) | ES2170114T3 (cs) |
| HU (1) | HU223844B1 (cs) |
| NO (1) | NO305206B1 (cs) |
| PL (1) | PL182615B1 (cs) |
| PT (1) | PT697408E (cs) |
| RU (1) | RU2156765C2 (cs) |
| SK (1) | SK281754B6 (cs) |
| TW (1) | TW425392B (cs) |
| UA (1) | UA35607C2 (cs) |
| ZA (1) | ZA956929B (cs) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19516483A1 (de) * | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US7049140B1 (en) * | 1999-04-29 | 2006-05-23 | Vanderbilt University | X-ray guided drug delivery |
| DE19958153A1 (de) * | 1999-12-03 | 2001-06-07 | Yamanouchi Pharma Co Ltd | Oxazolidinon-Derivate |
| DE10105989A1 (de) * | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
| US7306925B2 (en) | 2001-11-09 | 2007-12-11 | Vanderbilt University | Phage antibodies to radiation-inducible neoantigens |
| US7141588B2 (en) | 2002-02-25 | 2006-11-28 | Pfizer, Inc. | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
| AR038536A1 (es) * | 2002-02-25 | 2005-01-19 | Upjohn Co | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados |
| EP1594865A2 (en) * | 2003-02-07 | 2005-11-16 | Warner-Lambert Company LLC | Antibacterial agents |
| US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
| WO2005019214A1 (en) * | 2003-08-25 | 2005-03-03 | Warner-Lambert Company Llc | Novel antimicrobial aryloxazolidinone compounds |
| US7304050B2 (en) | 2003-09-16 | 2007-12-04 | Pfizer Inc. | Antibacterial agents |
| DK2484365T3 (da) | 2004-06-04 | 2013-12-02 | Scripps Research Inst | Sammensætninger og fremgangsmåde til behandling af neovaskulære sygdomme |
| WO2013019730A1 (en) | 2011-07-29 | 2013-02-07 | The Washington University | Antibodies to tip-1 and grp78 |
| EP3172222A4 (en) | 2014-07-24 | 2018-03-21 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
| WO2018148595A1 (en) | 2017-02-10 | 2018-08-16 | Washington University | Antibodies to tip1 and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2437388A (en) * | 1948-03-09 | Z-oxazolidone compounds and proc | ||
| FR2068423A1 (en) * | 1969-11-06 | 1971-08-27 | Delalande Sa | 3-phenyl-5-ethoxycarbonyl-2-oxazolidinones antiarrhythmics |
| FR2608604B1 (fr) * | 1986-12-19 | 1989-04-28 | Delalande Sa | Derives 5-hydroxyethyles de l'oxazolidinone-2, leurs procedes de preparation et leurs applications en therapeutique |
| US4866182A (en) * | 1988-02-18 | 1989-09-12 | Merrell Dow Pharmaceuticals Inc. | Cardiotonic alkanoyl and aroyl oxazolones |
| US5053393A (en) * | 1988-07-20 | 1991-10-01 | Monsanto Company | Novel platelet-aggregation inhibitor |
| US5084466A (en) * | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
| EP0417044A3 (en) * | 1989-09-07 | 1991-06-12 | Ciba-Geigy Ag | Oxazolidinones and thiones as plantgrowth regulators |
| FR2653017B1 (fr) * | 1989-10-17 | 1995-05-05 | Delalande Sa | Derives d'aryl-3 oxazolidinone-2, leur procede de preparation et leur application en therapeutique. |
| DE4017211A1 (de) * | 1990-05-29 | 1991-12-05 | Merck Patent Gmbh | Oxazolidinone |
| US5298516A (en) * | 1991-03-27 | 1994-03-29 | Sankyo Company, Limited | Thiazolidone compounds and method of using the same as a vasodilator |
| DE4405633A1 (de) * | 1993-05-01 | 1994-11-03 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DK0623615T3 (da) * | 1993-05-01 | 1999-12-13 | Merck Patent Gmbh | Adhæsionsreceptor-antagonister |
| DE4332384A1 (de) * | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
| CA2170661A1 (en) * | 1995-03-22 | 1996-09-23 | John K. Thottathil | Novel methods for the preparation of taxanes using oaxzolidine intermediates |
-
1994
- 1994-08-19 DE DE4429461A patent/DE4429461A1/de not_active Withdrawn
-
1995
- 1995-07-05 TW TW084106938A patent/TW425392B/zh not_active IP Right Cessation
- 1995-08-10 DE DE59510010T patent/DE59510010D1/de not_active Expired - Lifetime
- 1995-08-10 AT AT95112583T patent/ATE212339T1/de not_active IP Right Cessation
- 1995-08-10 DK DK95112583T patent/DK0697408T3/da active
- 1995-08-10 EP EP95112583A patent/EP0697408B1/de not_active Expired - Lifetime
- 1995-08-10 PT PT95112583T patent/PT697408E/pt unknown
- 1995-08-10 ES ES95112583T patent/ES2170114T3/es not_active Expired - Lifetime
- 1995-08-11 SK SK1001-95A patent/SK281754B6/sk unknown
- 1995-08-11 UA UA95083785A patent/UA35607C2/uk unknown
- 1995-08-14 AU AU28522/95A patent/AU698412B2/en not_active Ceased
- 1995-08-15 CZ CZ19952087A patent/CZ290984B6/cs not_active IP Right Cessation
- 1995-08-17 HU HU9502431A patent/HU223844B1/hu not_active IP Right Cessation
- 1995-08-17 CN CNB951152866A patent/CN1204889C/zh not_active Expired - Fee Related
- 1995-08-17 CA CA2156360A patent/CA2156360C/en not_active Expired - Fee Related
- 1995-08-18 NO NO953253A patent/NO305206B1/no not_active IP Right Cessation
- 1995-08-18 JP JP23210695A patent/JP3810833B2/ja not_active Expired - Fee Related
- 1995-08-18 PL PL95310070A patent/PL182615B1/pl not_active IP Right Cessation
- 1995-08-18 US US08/516,937 patent/US5614535A/en not_active Expired - Lifetime
- 1995-08-18 RU RU95113863/04A patent/RU2156765C2/ru not_active IP Right Cessation
- 1995-08-18 ZA ZA956929A patent/ZA956929B/xx unknown
- 1995-08-18 KR KR1019950025388A patent/KR100365870B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE212339T1 (de) | 2002-02-15 |
| PL182615B1 (pl) | 2002-02-28 |
| DE59510010D1 (de) | 2002-03-14 |
| EP0697408A1 (de) | 1996-02-21 |
| AU2852295A (en) | 1996-02-29 |
| CA2156360A1 (en) | 1996-02-20 |
| AU698412B2 (en) | 1998-10-29 |
| UA35607C2 (uk) | 2001-04-16 |
| NO953253D0 (no) | 1995-08-18 |
| CN1204889C (zh) | 2005-06-08 |
| US5614535A (en) | 1997-03-25 |
| KR960007586A (ko) | 1996-03-22 |
| SK100195A3 (en) | 1996-06-05 |
| TW425392B (en) | 2001-03-11 |
| CZ290984B6 (cs) | 2002-11-13 |
| DE4429461A1 (de) | 1996-02-22 |
| HU223844B1 (hu) | 2005-02-28 |
| NO953253L (no) | 1996-02-20 |
| CN1125575A (zh) | 1996-07-03 |
| DK0697408T3 (da) | 2002-04-15 |
| NO305206B1 (no) | 1999-04-19 |
| ES2170114T3 (es) | 2002-08-01 |
| CZ208795A3 (en) | 1996-06-12 |
| ZA956929B (en) | 1996-03-29 |
| KR100365870B1 (ko) | 2003-03-04 |
| CA2156360C (en) | 2011-01-11 |
| JP3810833B2 (ja) | 2006-08-16 |
| RU2156765C2 (ru) | 2000-09-27 |
| PL310070A1 (en) | 1996-03-04 |
| HUT76790A (en) | 1997-11-28 |
| EP0697408B1 (de) | 2002-01-23 |
| JPH0892227A (ja) | 1996-04-09 |
| PT697408E (pt) | 2002-07-31 |
| HU9502431D0 (en) | 1996-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4202438B2 (ja) | 接着性レセプター拮抗化合物 | |
| SK281754B6 (sk) | Derivát oxazolidinóndikarboxylovej kyseliny, spôsob jeho prípravy, farmaceutický prostriedok, ktorý ho obsahuje a jeho použitie | |
| SK112194A3 (en) | Oxazolidine derivative, method of its preparation and pharmaceutical agent which containt its | |
| AU670649B2 (en) | Piperazinderivate | |
| HUP9903716A2 (hu) | Alfa-integrin-gátló tirozinszármazékok | |
| SK282123B6 (sk) | Derivát oxazolidinónu, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje | |
| SK48494A3 (en) | Antagonists of adhesion receptors, method of their production and pharmaceutical agents on their base | |
| SK22195A3 (en) | Imidazo £1,2-a| pyridine derivatives, method of their production, pharmaceutical agents on their base, method of their production and their using | |
| CZ42996A3 (en) | Oxazolidinone derivative, process of its preparation and pharmaceutical preparation containing thereof | |
| KR20050105463A (ko) | 2환식 방향족 아미노산 및 이들의 중간체들의 제조 방법 | |
| SK14342001A3 (sk) | Dibenzoazulénové deriváty na liečbu trombózy, osteoporózy, artériosklerózy | |
| SK15522002A3 (sk) | Derivát esteru kyseliny karbaminovej ako inhibítor faktora Xa, spôsob jeho prípravy, jeho použitia a farmaceutický prostriedok, ktorý ho obsahuje | |
| MXPA96001659A (en) | Antagonists of the receiver of accession, procedure to prepare them, pharmaceutical compositions that contain them and its employment to prepare medicines, and fight against pharmacy | |
| MXPA98004971A (en) | Tyrosin derivatives as inhibitors of alpha-v-integr | |
| CZ2001141A3 (cs) | Derivát diacylhydrazinu jakožto integrinový inhibitor, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje |